Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Join the live Q&A on PrEP, the latest in HIV prevention. Text your questions to 713-526-1111 and tune in Monday to learn ...

A new HIV drug, lenacapavir, appears highly effective against strains circulating in Uganda, according to a study led by ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

Foster City, California Thursday, February 20, 2025, 12:00 Hrs [IST] ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New ...